Transforming Growth Factor Beta 3 (TGFB3) Antibody (FITC)

Background

TGFB3 is another member of the TGF-β family that is predominantly involved in embryonic development, tissue remodeling, and wound healing. TGFB3 regulates processes such as epithelial-mesenchymal transition (EMT), extracellular matrix (ECM) deposition, and immune suppression. It is highly expressed during palatogenesis, craniofacial development, and lung morphogenesis, where it plays an essential role in cell signaling and tissue architecture. TGFB3 facilitates proper scar formation and tissue repair by modulating fibroblast activation and ECM production while reducing excessive fibrosis. In cancer, TGFB3 contributes to tumor progression by inducing EMT and promoting metastatic dissemination. Mutations or dysregulation of TGFB3 are associated with cleft palate, cardiovascular abnormalities, and fibrotic diseases. Knockout models reveal impaired wound healing, disrupted tissue morphogenesis, and craniofacial defects, highlighting TGFB3’s role in tissue development, regeneration, and fibrotic regulation.